Overview of highly potent inhibitors of GLUT isoforms overexpressed in OC
| GLUT inhibitors | GLUT isoforms | Clinical phase | Main cell/animal models | Effective inhibitory concentration | Reference |
|---|---|---|---|---|---|
| 2-DG | GLUT1 | Phase Ι clinical trials | SKOV-3/TOV21 | 20 mmol/L | [84, 85] |
| RV | GLUT1 | In vitro assays | OVCAR3/OAW42 | 100 µmol/L | [86] |
| Ciglitazone | GLUT1 | In vitro and in vivo assays | A2780, NSG mice | 1 µmol/L | [87] |
| Silibinin | GLUT4 | In vitro assays | SKOV-3 | 100–200 µmol/L | [88] |
| BAY-876 | GLUT1 | In vitro and in vivo assays | SKOV-3/OVCAR-3/A2780 patient-derived xenograft | 60–180 nmol/L | [89] |
| STF31 | GLUT1 | In vitro assays | OVCAR5/TOV112D/OVCAR3 | 0.8–1.5 µmol/L | [51] |